You are not familiar with the T1D Exchange and if you are living with type 1 diabetes — well, you should be! This well-funded and forward-thinking organization is taking the bull by the horns, so to speak, in advancing T1D research and care.
Born out of the Helmsley Charitable Trust that has poured more than $300 million into research, treatments, technology, and solutions that will facilitate type 1 diabetes, T1D Exchange was launched in 2009 with a first focus on creating a nationwide T1D recorder and community system.
Now that platform hosts records for more than 30,000 T1D patients, a biorepository that stores and processes biological information for scientific investigation, and an online patient and caregiver community called Glu with over 16,500 enrolled members.
Back in August, the organization established a much-anticipated MyGlu Mobile App that lets members access the community resources and participate in patient-centered research on the move. (It’s IOS only for now and listed in the Apple shop under “myGlu.”)
1 hallmark of the Glu community is the “Question of the Day” feature, which also gets emailed to members and is currently a part of the program. Though some folks find this annoying, it will allow the org to gather unprecedented amounts of information on aspects of life with T1D never before studied, with questions like “Which kind of situational or psychological stress has the biggest influence on your BG levels?” And “Have you ever needed to ration your diabetes supplies?”
But do not be fooled — T1D ExChange is much more than an online community with a new program. They aim to revolutionize diabetes care with a wide approach that is three-pronged:
Patient-Centered Program: the growing Glu community, also various collaborations and polls all aimed at responding and listening to the patient voice.
Clinical Program: a collaborative system with dozens of studies underway across the country, for example, Replace BG Now research (for permitting insulin dosing decisions off CGM information), along with also a “Mini-Dose Glucagon” research (assessing the efficacy and safety of this treatment for non-severe hypoglycemia in adults with T1D).
Science Program: a “Living Biobank” that meets patients with clinical trials and shops 50,000+ blood samples to further research.
There is this unbelievable $5.2 million national health plan analyst, declared in Spring 2016, that T1D Exchange is currently shepherding alongside JDRF and the Helmsley Trust (which both donated $2.6 million) that aims to support and progress the T1D healthcare landscape by fixing three hurdles: T1D Unmet Needs, Barriers to Adoption, along with T1D Outcomes. Details about how that will materialize are coming.
Perhaps most exciting in the moment (and only up that our DiabetesMine street!!) Is the new yearly Diabetes Innovation Challenge program the group is kicking off this season. They’re collaborating with M2D2, a medical device startup incubator that is a joint venture at the University of Massachusetts Lowell and Worcester campuses.
As stated by the T1D Exchange spokes-folks: “It’s an open contest created to support and accelerate the development of novel therapies, devices and solutions in both type 1 and type 2 diabetes… supported by lead patrons American Diabetes Association (ADA) and JDRF, as well as Medtronic, Lilly, BD, J&J, and patrons from legal / investment firms.”
Judges come from ADA, JDRF and UMass Worcester Medical School, among others, and at least two finalists will be awarded around $150,000 cash or in-kind services.
They tell us they have culled down a list of almost 60 applicants to 30 semi-finalists “who have some really great and novel inventions from the diabetes space across 4 key classes — diagnostics, devices, therapeutics and technology.”
The Challenge consists of several events, including two semi-final events that took place Sept. 29 and Oct. 5; a Finals Event coming up Oct. 20, the evening before T1D Exchange’s yearly assembly; along with a Winners Showcase taking place the following day in their yearly assembly.
We thought you might be as curious as we were to know who the semi-finalists are, as explained in the contest tip sheet:
- Admetsys – in-hospital artificial pancreas
- Diabatech – insulin storage in the rural/urban slums of South Asia
- Enable Biosciences – Ultrasensitive auto-antibody test for population screening
- Encellin – encapsulation device solution for mobile treatment
- Glucosight – measuring sugar by pupillary response
- New England Breath Technologies – “pain-free sugar monitoring: only a breath away”
- Orgenesis – mobile replacement therapy
- OzStar Therapeutics – new combination treatment for type 2 diabetes
- Polyphotonix – diabetic retinopathy mask
- Prosenex – foot screening for peripheral neuropathy
- REMD – fully human monoclonal antibody against human glucagon receptor
- Sensulin – sugar reactive insulin
- Sigilon – transplanting human insulin-producing cells
- Zucara Therapeutics – medication to prevent hypoglycemia
- Biorasis – “smallest, most precise continuous glucose monitoring”
- CamMed – thin, elastic patch pump to get one or several injectable medicines
- Clinitech – digital Band-Aid for noninvasive glucose monitoring
- Fairbanks – publication therapies that will promote formation of new beta cells to replace those lost in diabetic patients)
- Glyscend – orally-administered intestinal coating that imitates the curative Advantages of bariatric surgery in T2 diabetes
- Integrated Medical – first fully-integrated, low-cost, implantable, wireless, continuous glucose monitoring platform
- Jupiter – noninvasive continuous glucose monitor
- Laxmi – cheap, painless band-aid type disposable daily limitation for wireless sugar measurements in interstitial fluid
- Nangiotx – returning blood flow to ischemic muscles in diabetics
- Novointestine – 3D Bioprinted gastrointestinal medication delivery system
- QSM – sensors inside wound dressings for detecting infection
- SFC – highly accurate and small double hormone pumping system
- Sporomex – publication bioengineering strategy for beta cell encapsulation
- Theranova – intra-peritoneal method of diabetes management for the development of an Artificial Pancreas
- UND – lipid-based little molecule as a potential drug to prevent and manage diabetic retinopathy
Wow, they sound pretty intriguing… guess we’ve got some Googling to do!
And needless to say, we’re very excited to find out who the winners are! We’ll discuss on social media of course.
Yet another note on innovation contests: take a look at the FDA’s new Precision Medicine App-a-Thon, where they’re calling for new programs that are “adware controls using the Linux operating system ‘wrapped’ about NGS software.” That challenge closes Oct. 28, so if you just happen to be qualified and interested, download the precisionFDA App-a-thon in a Box Toolkit and receive active innovating!
Since you know, #WeAreNotWaiting…
My, how we love to find that hashtag in action! 🙂
Disclaimer: Content created by the Diabetes Mine team. For additional information click here.
This content is made for Diabetes Mine, a customer health blog focused on the diabetes community. The content is not medically reviewed and does not adhere to Healthline’s editorial instructions. For more information about Healthline’s venture with Diabetes Mine, please click here.
Was this post useful? YesNo
We are not able to offer personal wellness information, but we’ve partnered with trusted telehealth provider Amwell, who will hook you up with a physician. Try Amwell telehealth for $1 by using the code HEALTHLINE.
Use code HEALTHLINE
If you are facing a medical emergency, phone the local emergency services immediately, or visit the closest emergency room or urgent care center.
We are sorry, an error occurred.
We cannot collect your comments at this moment. Nonetheless, your feedback is important to us. Please try again later.
We love your helpful comments!
Let us be friends — join our Facebook community.
Thanks for your useful suggestion.
We’ll discuss your response with our medical review team, who’ll upgrade any incorrect information in the article.
Thanks for sharing your comments.
We are sorry you are unsatisfied with what you have read. Your ideas will help us improve this article.
Composed by on Sep 21, 2017
Composed by on Jul 13, 2017
Composed by on Dec 14, 2017